Sanofi and GSK to provide UK with 60m doses of Covid-19 vaccine

French pharmaceutical giant Sanofi and GlaxoSmithKline have agreed to provide the UK with as many as 60.0m doses of their Covid-19 vaccine candidate, subject to final contract.

The vaccine candidate employs a combination of Sanofi's recombinant protein-based technology and GSK's pandemic adjuvant technology.

Both firms also reiterated their commitment to making both drugs available globally.

GlaxoSmithKline was scheduled to report second quarter sales at noon the same day.